155 related articles for article (PubMed ID: 11190577)
21. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
22. Protein kinase C activation modulates pro- and anti-apoptotic signaling pathways.
Meinhardt G; Roth J; Totok G
Eur J Cell Biol; 2000 Nov; 79(11):824-33. PubMed ID: 11139146
[TBL] [Abstract][Full Text] [Related]
23. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity.
Wang H; Mohammad RM; Werdell J; Shekhar PV
Int J Mol Med; 1998 Jun; 1(6):915-23. PubMed ID: 9852625
[TBL] [Abstract][Full Text] [Related]
24. Protein kinase C inhibitors as novel anticancer drugs.
Goekjian PG; Jirousek MR
Expert Opin Investig Drugs; 2001 Dec; 10(12):2117-40. PubMed ID: 11772309
[TBL] [Abstract][Full Text] [Related]
25. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
[TBL] [Abstract][Full Text] [Related]
26. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
[TBL] [Abstract][Full Text] [Related]
27. Analogs of staurosporine: potential anticancer drugs?
Gescher A
Gen Pharmacol; 1998 Nov; 31(5):721-8. PubMed ID: 9809468
[TBL] [Abstract][Full Text] [Related]
28. The pros and cons of targeting protein kinase C (PKC) in the management of cancer patients.
Leskow FC; Krasnapolski MA; Urtreger AJ
Curr Pharm Biotechnol; 2011 Nov; 12(11):1961-73. PubMed ID: 21470133
[TBL] [Abstract][Full Text] [Related]
29. Effect of novel modulators of protein kinase C activity upon chemotherapy-induced differentiation and apoptosis in myeloid leukemic cells.
Meinhardt G; Eppinger E; Schmidmaier R
Anticancer Drugs; 2002 Aug; 13(7):725-33. PubMed ID: 12187329
[TBL] [Abstract][Full Text] [Related]
30. Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides.
Masanek U; Stammler G; Volm M
J Exp Ther Oncol; 2002; 2(1):37-41. PubMed ID: 12415618
[TBL] [Abstract][Full Text] [Related]
31. Effects of protein kinase C modulators on multidrug resistance in human glioma cells.
Matsumoto T; Tani E; Yamaura I; Miyaji K; Kaba K
Neurosurgery; 1995 Mar; 36(3):565-71; discussion 572. PubMed ID: 7538636
[TBL] [Abstract][Full Text] [Related]
32. Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.
Wang S; Wang Z; Grant S
Mol Pharmacol; 2003 Jan; 63(1):232-42. PubMed ID: 12488556
[TBL] [Abstract][Full Text] [Related]
33. Preclinical and clinical development of novel agents that target the protein kinase C family.
Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells.
Schwartz GK; Haimovitz-Friedman A; Dhupar SK; Ehleiter D; Maslak P; Lai L; Loganzo F; Kelsen DP; Fuks Z; Albino AP
J Natl Cancer Inst; 1995 Sep; 87(18):1394-9. PubMed ID: 7658500
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.
Pallis M; Turzanski J; Higashi Y; Russell N
Leuk Lymphoma; 2002 Jun; 43(6):1221-8. PubMed ID: 12152989
[TBL] [Abstract][Full Text] [Related]
36. The potential for isoenzyme-selective modulation of protein kinase C.
Hofmann J
FASEB J; 1997 Jul; 11(8):649-69. PubMed ID: 9240967
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2.
Wang Q; Worland PJ; Clark JL; Carlson BA; Sausville EA
Cell Growth Differ; 1995 Aug; 6(8):927-36. PubMed ID: 8547221
[TBL] [Abstract][Full Text] [Related]
38. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity.
Le XF; Marcelli M; McWatters A; Nan B; Mills GB; O'Brian CA; Bast RC
Oncogene; 2001 Dec; 20(57):8258-69. PubMed ID: 11781840
[TBL] [Abstract][Full Text] [Related]
39. The role of protein kinase C-alpha (PKC-alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen.
Hanauske AR; Sundell K; Lahn M
Curr Pharm Des; 2004; 10(16):1923-36. PubMed ID: 15180529
[TBL] [Abstract][Full Text] [Related]
40. Selective modulation of P-glycoprotein's ATPase and anion efflux regulation activities with PKC alpha and PKC epsilon in Sf9 cells.
Idriss H; Urquidi V; Basavappa S
Cancer Chemother Pharmacol; 2000; 46(4):287-92. PubMed ID: 11052626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
